Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 2001 Aug;10(4):199–208. doi: 10.1080/09629350123139

Establishment of a consistent L929 bioassay system for TNF-alpha quantitation to evaluate the effect of lipopolysaccharide, phytomitogens and cytodifferentiation agents on cytotoxicity of TNF-alpha secreted by adherent human mononuclear cells.

M Y Shiau 1, H L Chiou 1, Y L Lee 1, T M Kuo 1, Y H Chang 1
PMCID: PMC1781708  PMID: 11577996

Abstract

TUMOR necrosis factor-alpha (TNF-alpha) plays an important role in the pathogenesis of rheumatoid arthritis. The present study was to evaluate the effects of lipopolysaccharide (LPS), phytomitogens and cytodifferentiation agents on cytotoxicity of TNF-alpha secreted by adherent human mononuclear cells (AMC). TNF-alpha cytotoxicity in LPS-treated, phytomitogen-treated, and cytodifferentiation agent-treated AMC supernatants were analyzed by the L929 bioassay system. Our results showed that LPS could induce homogeneous TNF-alpha production by AMC whereas, in addition to TNF-alpha, phytomitogens could also induce other TNF-like factors. Neither methotrexate, retinoic acid nor sodium butyrate can inhibit TNF-alpha cytotoxicity, while hexamethylene bisacetamide could not only inhibit TNF-alpha cytotoxicity but also TNF-alpha inducing ability of LPS to AMC.

Full Text

The Full Text of this article is available as a PDF (285.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baarsch M. J., Wannemuehler M. J., Molitor T. W., Murtaugh M. P. Detection of tumor necrosis factor alpha from porcine alveolar macrophages using an L929 fibroblast bioassay. J Immunol Methods. 1991 Jun 24;140(1):15–22. doi: 10.1016/0022-1759(91)90121-u. [DOI] [PubMed] [Google Scholar]
  2. Brennan F. M., Chantry D., Jackson A., Maini R., Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989 Jul 29;2(8657):244–247. doi: 10.1016/s0140-6736(89)90430-3. [DOI] [PubMed] [Google Scholar]
  3. Dayer J. M., Beutler B., Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985 Dec 1;162(6):2163–2168. doi: 10.1084/jem.162.6.2163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Denizot F., Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986 May 22;89(2):271–277. doi: 10.1016/0022-1759(86)90368-6. [DOI] [PubMed] [Google Scholar]
  5. Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods. 1986 Dec 4;95(1):99–105. doi: 10.1016/0022-1759(86)90322-4. [DOI] [PubMed] [Google Scholar]
  6. Flick D. A., Gifford G. E. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods. 1984 Mar 30;68(1-2):167–175. doi: 10.1016/0022-1759(84)90147-9. [DOI] [PubMed] [Google Scholar]
  7. Galloway C. J., Madanat M. S., Mitra G. Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity. J Immunol Methods. 1991 Jun 24;140(1):37–43. doi: 10.1016/0022-1759(91)90124-x. [DOI] [PubMed] [Google Scholar]
  8. Hay H., Cohen J. Studies on the specificity of the L929 cell bioassay for the measurement of tumour necrosis factor. J Clin Lab Immunol. 1989 Jul;29(3):151–155. [PubMed] [Google Scholar]
  9. Kingsley G., Pitzalis C., Panayi G. S. Immunogenetic and cellular immune mechanisms in rheumatoid arthritis: relevance to new therapeutic strategies. Br J Rheumatol. 1990 Feb;29(1):58–64. doi: 10.1093/rheumatology/29.1.58. [DOI] [PubMed] [Google Scholar]
  10. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  11. Müzes G., Vien C. V., Gonzalez-Cabello R., Gergely P., Feher J. A simple assay for tumor necrosis factor using HEp-2 target cells. J Clin Lab Immunol. 1989 Sep;30(1):41–44. [PubMed] [Google Scholar]
  12. O'Callaghan J. W., Forrest M. J., Brooks P. M. Inhibition of neutrophil chemotaxis in methotrexate-treated rheumatoid arthritis patients. Rheumatol Int. 1988;8(1):41–45. doi: 10.1007/BF00541349. [DOI] [PubMed] [Google Scholar]
  13. Olsen N. J., Callahan L. F., Pincus T. Immunologic studies of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 1987 May;30(5):481–488. doi: 10.1002/art.1780300501. [DOI] [PubMed] [Google Scholar]
  14. Olsen N. J., Murray L. M. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum. 1989 Apr;32(4):378–385. doi: 10.1002/anr.1780320404. [DOI] [PubMed] [Google Scholar]
  15. Segal R., Mozes E., Yaron M., Tartakovsky B. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum. 1989 Apr;32(4):370–377. doi: 10.1002/anr.1780320403. [DOI] [PubMed] [Google Scholar]
  16. Shalaby M. R., Aggarwal B. B., Rinderknecht E., Svedersky L. P., Finkle B. S., Palladino M. A., Jr Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol. 1985 Sep;135(3):2069–2073. [PubMed] [Google Scholar]
  17. Sugarman B. J., Aggarwal B. B., Hass P. E., Figari I. S., Palladino M. A., Jr, Shepard H. M. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985 Nov 22;230(4728):943–945. doi: 10.1126/science.3933111. [DOI] [PubMed] [Google Scholar]
  18. Weinblatt M. E., Coblyn J. S., Fox D. A., Fraser P. A., Holdsworth D. E., Glass D. N., Trentham D. E. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985 Mar 28;312(13):818–822. doi: 10.1056/NEJM198503283121303. [DOI] [PubMed] [Google Scholar]
  19. Weyand C. M. New insights into the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2000 Jun;39 (Suppl 1):3–8. doi: 10.1093/oxfordjournals.rheumatology.a031491. [DOI] [PubMed] [Google Scholar]
  20. Yocum D. E., Esparza L., Dubry S., Benjamin J. B., Volz R., Scuderi P. Characteristics of tumor necrosis factor production in rheumatoid arthritis. Cell Immunol. 1989 Aug;122(1):131–145. doi: 10.1016/0008-8749(89)90154-8. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES